-
公开(公告)号：US20220387448A1
公开(公告)日：2022-12-08
申请号：US17843506
申请日：2022-06-17
摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
公开(公告)号：US20220105027A1
公开(公告)日：2022-04-07
申请号：US17273392
申请日：2019-09-06
IPC分类号： A61K9/00 , A61K31/566 , A61K47/10 , A61K31/255 , A61K47/20 , A61K47/02
摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described.
-
公开(公告)号：US20200281939A1
公开(公告)日：2020-09-10
申请号：US16644993
申请日：2018-09-07
摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
公开(公告)号：US20190076352A1
公开(公告)日：2019-03-14
申请号：US16081068
申请日：2017-03-02
IPC分类号： A61K9/00 , A61K31/57 , A61K47/10 , A61K47/20 , A61K47/02 , A61K47/14 , A61P15/18 , A61P29/02 , A61P35/00
摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
-
-
搜索结果
4 条记录 (耗时 0.012 秒)
